
The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.

The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after suboptimal first-line therapy.

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

Cabozantinib plus nivolumab and ipilimumab maintained a progression-free survival benefit at 45 months vs placebo in advanced kidney cancer.

Orca-T improved overall survival vs post-transplant cyclophosphamide in a retrospective analysis.

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final CheckMate 9ER trial results.

Lenvatinib plus belzutifan showed durable activity and a consistent safety profile in advanced clear cell renal cell carcinoma after prior treatment.

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in lenalidomide-refractory multiple myeloma.

Obecabtagene autoleucel improved survival and response durability in B-cell acute lymphoblastic leukemia patients with minimal residual disease–negative remission.

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data.

Enfortumab vedotin plus pembrolizumab doubled progression-free survival vs chemotherapy in urothelial cancer.

Datopotamab deruxtecan showed promising activity in advanced urothelial cancer in a phase 1 study.

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 Genitourinary Cancers Symposium.

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss some specific practices and policies that have been most effective at their institution and how these may be adopted by other practices.

A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.

Axatilimab demonstrated consistent response and durability in chronic graft-versus-host disease, regardless of prior treatments, in a phase 1 AGAVE-201 trial analysis.

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the phase 3 MOTION trial.

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss how medical mistrust has impacted participation in oncology clinical trials.

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

In a retrospective cohort of patients with severe chronic GVHD, combination axatilimab with other GVHD therapies led to clinical benefit.

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma.

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.